FDA Requires New Heart Failure Warnings on Onglyza Label - Legal Examiner
FDA Requires New Heart Failure Warnings on Onglyza LabelLegal ExaminerThe FDA has recently announced that new warnings will be added to the labels of both Onglyza (saxagliptin) and Nesina (alogliptin), cautioning that they may increase the risk for heart failure, especially in patients who already have kidney disease or .
Merck's 2Q16 Estimates: Expect Operational Growth in RevenuesMarket RealistThe competitors for Januvia and its combination version Janumet are Onglyza, jointly made by Bristol-Myers Squibb (BMY) and AstraZeneca (AZN), and Galvus from Novartis (NVS).
Which Growth Platforms Will Drive AstraZeneca's 2Q16 Earnings? - Market Realist
Market RealistWhich Growth Platforms Will Drive AstraZeneca's 2Q16 Earnings?Market RealistThe diabetes franchise includes drugs like Onglyza, Bydureon, Byetta, and Farxiga.
Why Analysts Think AstraZeneca's Revenues Will Fall in 2Q16 - Market Realist
Why Analysts Think AstraZeneca's Revenues Will Fall in 2Q16Market RealistAnalysts expect strong performances from Brilinta, Onglyza, Bydureon, and Farxiga to drive the growth of this segment for 2Q16 while there might be a decline in revenues of Byetta and legacy drugs Crestor and Atacand.
FDA warns on heart failure risk associated with Onglyza, Nesina - BioPharma Dive
FDA warns on heart failure risk associated with Onglyza, NesinaBioPharma DiveThe FDA is adding new warnings to the labels for AstraZeneca's Onglyza (saxagliptin) and Takeda's Nesina (alogliptin) after an internal safety review found an increased risk of heart failure with the two diabetes drugs.